drugset / Trial / NCT02553135

Choroideremia Gene Therapy Clinical Trial

NCT02553135 ↗

Phase 2 Completed 6 enrolled Byron Lam
NaSingle-groupOpen-labelTreatment

Summary

Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients will be required to attend a total of 11 study visits over a 24 month period with an additional 3 year follow-up.

Timeline

Start
2015-09
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AAV2-REP1 Gene therapy (AAV / viral vector) 1e+11 vg Other

Indications